Literature DB >> 25941551

Rho kinase inhibitors: potentially versatile therapy for the treatment of cardiovascular diseases and more.

Ahmed F Abdel-Magid1.   

Abstract

Entities:  

Year:  2015        PMID： 25941551      PMCID： PMC4416433          DOI： 10.1021/acsmedchemlett.5b00079

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN： 1948-5875            Impact factor:   4.345


× No keyword cloud information.
  3 in total

Review 1.  Rho kinases in cardiovascular physiology and pathophysiology: the effect of fasudil.

Authors:  Jianjian Shi; Lei Wei
Journal:  J Cardiovasc Pharmacol       Date:  2013-10       Impact factor: 3.105

Review 2.  Rho-kinase as a therapeutic target in vascular diseases: striking nitric oxide signaling.

Authors:  Gopi Krishna Kolluru; Syamantak Majumder; Suvro Chatterjee
Journal:  Nitric Oxide       Date:  2014-09-06       Impact factor: 4.427

Review 3.  Rho kinase inhibitors: a patent review (2012 - 2013).

Authors:  Yangbo Feng; Philip V LoGrasso
Journal:  Expert Opin Ther Pat       Date:  2013-11-27       Impact factor: 6.674
  3 in total
  1 in total

1.  ROCK inhibitor Y-27632 inhibits the growth, migration, and invasion of Tca8113 and CAL-27 cells in tongue squamous cell carcinoma.

Authors:  Zhi-Ming Wang; Dong-Sheng Yang; Jie Liu; Hong-Bo Liu; Ming Ye; Yu-Fei Zhang
Journal:  Tumour Biol       Date:  2015-10-14
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.